Compare DexCom, Inc. (DXCM) vs KB Financial Group, Inc. (KB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs KB Financial Group, Inc. — how do they compare? DexCom, Inc. trades at $78.55 (market cap $28.06B), while KB Financial Group, Inc. trades at $122.32 (market cap $41.90B). The key difference: KB Financial Group, Inc. is the larger of the two by market cap, and KB Financial Group, Inc. pays a 2.58% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | KB | |
|---|---|---|
Market Cap | $28.06B | $41.90B |
Sector | Health | Financials |
52-Week High | $89.53 | $123.25 |
52-Week Low | $54.84 | $77.50 |
Enterprise Value | $27.03B | — |
Dividend Yield | — | 2.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.
The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.
KB Financial Group's stock trades at $121.02, showing modest daily gains. The technical outlook is bullish with strong moving average signals, though oscillators are neutral. Fundamentally, the company demonstrates consistent revenue and net income growth, with a trailing P/E of 11.69 and strong net margin of 27.82%. Recent quarterly earnings have consistently beaten expectations, and the company is diversifying into non-banking operations, which now contribute 43% of earnings according to Seeking Alpha (2026-07-09).
The outlook is positive with earnings momentum and strategic diversification providing stability, though risks include potential overbought technical conditions and execution challenges in non-banking expansion. Analyst sentiment is mixed with a 33% buy rating, indicating cautious optimism about the company's growth trajectory and capital distribution plans.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About KB Financial Group, Inc.
KB Financial is the parent company of KB Kookmin Bank, Korea's largest commercial bank, with a 13.1% share of loans as of 2021. Its predecessor banks were established in the 1960s as government policy banks and privatized in the 1990s. Its credit card subsidiary KB Kookmin Card is the number-three player behind Shinhan Card and Samsung Card. KB has in recent years expanded its nonbank business by buying LIG Insurance and Hyundai Securities, making KB a top-five player in nonlife insurance and in securities, and most recently by buying Prudential Life Insurance Korea. It also has KB Capital, which provides leasing and installment finance.
Read more on KB →
